Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia
Wolfgang Högler(Johannes Kepler University of Linz), Michael P. Whyte(Shriners Hospitals for Children - St. Louis), Erik A. Imel(Indiana University – Purdue University Indianapolis), Anthony A. Portale(University of California, San Francisco), William van’t Hoff(Great Ormond Street Hospital), Alison Skrinar, Annemieke M. Boot(Erasmus MC - Sophia Children’s Hospital), Agnès Linglart(Assistance Publique – Hôpitaux de Paris), Raja Padidela(University of Groningen), Javier San Martín(Universidad Nacional de Educación a Distancia), Meng Mao(Guiyang Medical University), Thomas O. Carpenter(Yale University)
Cited by 0
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Global Consensus Recommendations on Prevention and Management of Nutritional Rickets
|The Journal of Clinical Endocrinology & Metabolism|2016|1.1k
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China
|The Lancet|2021|579
SLC34A3 Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter NaPi-IIc in Maintaining Phosphate Homeostasis
|The American Journal of Human Genetics|2006|493
Bone Mineral Density in Children and Adolescents: Relation to Puberty, Calcium Intake, and Physical Activity<sup>1</sup>
|The Journal of Clinical Endocrinology & Metabolism|1997|488